These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20431339)

  • 21. Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.
    Epstein SL
    Am J Epidemiol; 2018 Dec; 187(12):2603-2614. PubMed ID: 30084906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Confronting the next pandemic--workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010.
    Hardy S; Eichelberger M; Griffiths E; Weir JP; Wood D; Alfonso C
    Influenza Other Respir Viruses; 2011 Nov; 5(6):438-42. PubMed ID: 21668676
    [No Abstract]   [Full Text] [Related]  

  • 24. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
    Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
    Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.
    Kwak C; Nguyen QT; Kim J; Kim TH; Poo H
    J Microbiol Biotechnol; 2021 Feb; 31(2):304-316. PubMed ID: 33263336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.
    He XS; Holmes TH; Sanyal M; Albrecht RA; García-Sastre A; Dekker CL; Davis MM; Greenberg HB
    J Infect Dis; 2015 Apr; 211(7):1051-9. PubMed ID: 25336731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Swine flu outbreak. China first to vaccinate against novel H1N1 virus.
    Stone R
    Science; 2009 Sep; 325(5947):1482-3. PubMed ID: 19762610
    [No Abstract]   [Full Text] [Related]  

  • 29. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study.
    McVernon J; Laurie K; Barr I; Kelso A; Skeljo M; Nolan T
    Influenza Other Respir Viruses; 2011 Jan; 5(1):7-11. PubMed ID: 21138535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.
    Muller RB; Maier R; Hoschler K; Zambon M; Ludewig B; Herrmann M; Schulze-Koops H; von Kempis J
    Clin Exp Rheumatol; 2013; 31(5):723-30. PubMed ID: 23806224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine.
    De Groot AS; Ardito M; McClaine EM; Moise L; Martin WD
    Vaccine; 2009 Sep; 27(42):5740-7. PubMed ID: 19660593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
    Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
    PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients.
    Rambal V; Müller K; Dang-Heine C; Sattler A; Dziubianau M; Weist B; Luu SH; Stoyanova A; Nickel P; Thiel A; Neumann A; Schweiger B; Reinke P; Babel N
    Med Microbiol Immunol; 2014 Feb; 203(1):35-45. PubMed ID: 24057515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1).
    Barrett PN; Ehrlich HJ
    Lancet Infect Dis; 2011 Jul; 11(7):496-7; author reply 497-8. PubMed ID: 21700237
    [No Abstract]   [Full Text] [Related]  

  • 36. Against the new H1N1 influenza (swine influenza): vaccinate or don't vaccinate (all)? That is currently the question!
    Doerr HW; Allwinn R; Cinatl J
    Infection; 2009 Oct; 37(5):379-80. PubMed ID: 19768383
    [No Abstract]   [Full Text] [Related]  

  • 37. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination.
    Wagar LE; Rosella L; Crowcroft N; Lowcock B; Drohomyrecky PC; Foisy J; Gubbay J; Rebbapragada A; Winter AL; Achonu C; Ward BJ; Watts TH
    PLoS One; 2011; 6(11):e28063. PubMed ID: 22132212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.
    Haralambieva IH; Painter SD; Kennedy RB; Ovsyannikova IG; Lambert ND; Goergen KM; Oberg AL; Poland GA
    PLoS One; 2015; 10(3):e0122282. PubMed ID: 25816015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.
    Herrera MT; Gonzalez Y; Juárez E; Hernández-Sánchez F; Carranza C; Sarabia C; Guzman-Beltran S; Manjarrez ME; Muñoz-Torrico M; Garcia-Garcia L; Sada E; Torres M
    BMC Infect Dis; 2013 Nov; 13():544. PubMed ID: 24238117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.